Project description:This SuperSeries is composed of the following subset Series: GSE30758: Epigenome analysis of normal cells from the uterine cervix in a nested prospective case control study within the ARTISTIC trial GSE30759: Epigenome analysis of normal and cancer tissue from the uterine cervix Refer to individual Series
Project description:The Illumina Infinium 27k Human DNA methylation Beadchip v1.2 was used to obtain DNA methylation profiles across approximately 27,000 CpGs in normal cells from the uterine cervix (liquid based cytology samples), obtained from 152 women in a nested prospective case-control study within the ARTISTIC trial. Out of the 152 women, 75 developed a cervical intraepitelial neoplasia of grade 2 or higher (CIN2+) after 3 years of sample collection. The rest of women (77) remained disease free (CIN2-).
Project description:The Illumina Infinium 27k Human DNA methylation Beadchip v1.2 was used to obtain DNA methylation profiles across approximately 27,000 CpGs in normal cells from the uterine cervix (liquid based cytology samples), obtained from 152 women in a nested prospective case-control study within the ARTISTIC trial. Out of the 152 women, 75 developed a cervical intraepitelial neoplasia of grade 2 or higher (CIN2+) after 3 years of sample collection. The rest of women (77) remained disease free (CIN2-). Bisulphite converted DNA from the 152 samples were hybridised to the Illumina Infinium 27k Human Methylation Beadchip v1.2
Project description:We identified an altered miRNA expression in adenocarcinoma of the uterine cervix compared with normal cervix and futhermore analyzed their association with clinicopthologic characteristics.
Project description:Uterine cervix normal SAGE, CGAP non-normalized SAGE library, bulk method , HPV negative This GEO Series was created by the GEO staff as part of a cleanup effort to ensure that all GEO Samples are included within a Series entry.
Project description:We identified an altered miRNA expression in adenocarcinoma of the uterine cervix compared with normal cervix and futhermore analyzed their association with clinicopthologic characteristics. miRNA expression was measured in four cancerous tissues from the cervical adenocarcinoma and four non-cancerous from the normal uterine cerivx respectively, all of which were obtained from different donors.
Project description:Small cell neuroendocrine carcinoma (SCNEC) of the uterine cervix is a rare disease with a poor prognosis. The lack of established disease models has hampered therapy development. We established a panel of organoid from patients of SCNEC of the uterine cervix. Sensitivity assays against clinically used drugs revealed remarkable variations between the lines, and we successfully identified specific gene sets which likely contribute to the sensitivity to the tested drugs. Of note, we found one line which was exceptionally sensitive to irinotecan, and investigated the mode of action in the case. Chemotherapeutic drug sensitivity assays using SCNEC CTOS lines obtained from primary patient samples with a high success rate may provide useful information for treating SCNEC.
Project description:The endothelin receptor antagonist atrasentan improved kidney outcomes in the SONAR trial for type 2 diabetes and chronic kidney disease (NCT01858532), though individual responses varied. To identify molecular biomarkers of atrasentan response and outcome, we conducted a nested case-control proteomics study (N=180) within the SONAR trial population and identified urinary clusterin (uCLU) as the top candidate. Transcriptomic analyses of human kidney biopsies at tissue and single cell level from independent cohorts revealed higher CLU mRNA levels associated with worse kidney function and outcomes. An endothelin signaling activation score derived from pathway genes was reduced by atrasentan in mice with diabetic kidney disease. In the SONAR trial (N=3,060), higher uCLU predicted worse outcomes, while atrasentan reduced uCLU by 42.6% over six weeks. Early uCLU changes independently predict improved kidney outcomes. In summary, uCLU is associated with kidney disease progression and response to atrasentan treatment, supporting its potential as a pharmacodynamic biomarker to target therapy.
